Navigation Links
Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
Date:5/15/2012

SOUTH EASTON, Mass., May 15, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2012 financial results and to provide a business update.  Anyone interested may listen to the teleconference either by telephone or through a live web-cast.  The teleconference and web-cast information is provided below:

Date:  Wednesday, May 16, 2012
Time: 4:15 p.m. Eastern Daylight Time (EDT)

To attend this teleconference via web-cast, please visit the Company's website:
www.pressurebiosciences.com

To attend this teleconference via telephone:
Dial-in: (888) 383-9147

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call ends through June 16, 2012, and will be accessible through the Company's website. 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT").  PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market.  PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions.  PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Investor Contacts:
Pressure BioSciences, Inc.
Richard T. Schumacher, President & CEO
Joseph Damasio, Jr., VP of Finance & Administration
(
T) 508-230-1828


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Europe Patient Monitoring Market Outlook to 2017 - Fetal Monitors, Multiparameter Patient Monitoring, Neonatal Monitors, Non-Invasive Blood Pressure Monitors, Remote Patient Monitoring and Others
4. North America Patient Monitoring Market Outlook to 2017 - Fetal Monitors, Multiparameter Patient Monitoring, Neonatal Monitors, Non-Invasive Blood Pressure Monitors, Remote Patient Monitoring and Others
5. Femasys Receives FDA 510(k) Clearance for First Low Pressure HSG Device
6. ICU Medical Launches Neutron™ Needlefree Catheter Patency Device With Constant Neutral Pressure Backed by a $100,000 Guarantee to Reduce Catheter Occlusions
7. Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets
8. iHealth Labs Blood Pressure Self-Monitoring System Gets Nationwide Distribution
9. FDA: Treatment With Angiotensin Receptor Blockers for High Blood Pressure Does Not Increase Risk of Cancer
10. HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting
11. Wellsense Unveils First-Ever Bedside Patient Pressure Mapping System Designed to Assist Caregivers in Effectively Repositioning Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Companion animal ... in pets such as canine, avian and feline. ... types such as Attenuated Live Vaccines, Conjugate Vaccines, ... and Recombinant Vaccines. Attenuated live vaccines are derived ... which have been weakend under laboratory conditions. Conjugate ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental ... with dental fear and require sedation to receive dental care. The doctors offer three ... procedures, from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... in unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as ... premier society for this important science. , The Teratology Society ...
Breaking Medicine News(10 mins):